Search results for "Prognostic variable"

showing 10 items of 23 documents

Prognostic Factors of Papillary Renal Cell Carcinoma: Results From a Multi-Institutional Series After Pathological Review

2009

We examined papillary renal cell carcinoma prognostic variables and validated the 2002 UICC TNM staging system in a multicenter analysis.From 10 urological institutions in Germany followup data were collected on a total of 675 patients with papillary renal cell carcinoma. Central pathological review was done to validate external histopathological diagnoses. The Kaplan-Meier method was used to derive cumulative cancer specific and overall survival, and the log rank test was used to compare the curves of 2 or more groups. For multivariate analysis of prognostic factors Cox regression analysis was done. All proportional hazard assumptions were systemically verified using the Grambsch-Therneau …

MaleOncologymedicine.medical_specialtyPathologyPrognostic variableUrologyTNM staging systemRenal cell carcinomaInternal medicinemedicineCarcinomaHumansCarcinoma Renal CellNeoplasm StagingRetrospective StudiesPapillary renal cell carcinomasProportional hazards modelbusiness.industryCancerMiddle AgedPrognosismedicine.diseaseKidney NeoplasmsSurvival RateLog-rank testFemalebusinessJournal of Urology
researchProduct

Prognostic implications of arterial blood gases in acute decompensated heart failure

2010

The prognostic value of arterial blood gases (ABG) in patients with acute decompensated heart failure (ADHF) is not well-established. We therefore conducted the present study to determine the relationship between ABG on admission and long-term mortality in patients with ADHF.We studied 588 patients consecutively admitted to our department with ADHF. ABG and classical prognostic variables were determined at patients' arrival to the emergency department. The independent association among the main variables of ABG (pO2, pCO2 and pH) and mortality was assessed with Cox regression analysis.At a median follow-up of 23months, 221 deaths (37.6%) were registered. 308 (52.4%), 54 (9.2%) and 50 (8.5%)…

MalePrognostic variablemedicine.medical_specialtyAcute decompensated heart failureHyperoxiaSeverity of Illness IndexVentricular Function LeftpCO2HypoxemiaCause of DeathInternal medicineInternal MedicinemedicineHumansHypoxiaAgedRetrospective StudiesAcidosisHeart FailureProportional hazards modelbusiness.industryEmergency departmentCarbon DioxidePrognosismedicine.diseaseOxygenSurvival RateSpainCardiologyArterial bloodBlood Gas Analysismedicine.symptombusinessFollow-Up StudiesEuropean Journal of Internal Medicine
researchProduct

Incidence and types of complications after ablative oral cancer surgery with primary microvascular free flap reconstruction.

2015

Background: The aims of the study were 1) to evaluate the incidence and types of postoperative complications after ablative oral cancer surgery with primary free flap reconstruction and 2) identify prognostic variables for postoperative complications. Material and Methods: Desired data was retrieved from a computer database at the department of Oral and Maxillofacial Department, Queen Elisabeth hospital Birmingham, United Kingdom, between June 2007 and October 2012. Logistic regression was used to study relationships between preoperative variables and postoperative outcomes. Results: The study population consisted 184 patients, comprising 189 composite resections with reconstruction. Compli…

MalePrognostic variablemedicine.medical_specialtyOdontologíaFree flapLogistic regressionFree Tissue FlapsPostoperative ComplicationsSDG 3 - Good Health and Well-beingAblative caseMedicineHumansGeneral DentistryRetrospective StudiesMouth neoplasmbusiness.industryIncidence (epidemiology)IncidenceResearchRetrospective cohort studyLength of StayMiddle Aged:CIENCIAS MÉDICAS [UNESCO]PrognosisCiencias de la saludSurgeryOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASMicrovessels/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingPopulation studySurgeryFemaleMouth NeoplasmsOral SurgerybusinessMedicina oral, patologia oral y cirugia bucal
researchProduct

Validation of a Model for Identification of Patients at Intermediate to High Risk for Complications Associated With Acute Symptomatic Pulmonary Embol…

2015

For patients with acute symptomatic pulmonary embolism (PE), the Bova score classifies their risk for PE-related complications within 30 days after diagnosis. The original Bova score was derived from 2,874 normotensive patients with acute PE who participated in one of six prospective PE studies.We retrospectively assessed the validity of the Bova risk model in normotensive patients with acute PE diagnosed in an academic urban ED. Two clinician investigators used baseline data for the model's four prognostic variables to stratify patients into the three Bova risk stages (I-III) for 30-day PE-related complications. Intraclass correlation coefficient (ICC) and the κ statistic were used to asse…

MalePulmonary and Respiratory Medicinemedicine.medical_specialtyPrognostic variableIntraclass correlationBlood PressureCritical Care and Intensive Care MedicineRisk AssessmentHeart RateInternal medicine80 and overmedicineVentricular FunctionHumansStage (cooking)AgedRetrospective StudiesAged 80 and overFramingham Risk Scorebusiness.industryTroponin IReproducibility of ResultsRetrospective cohort studyMiddle AgedPrognosismedicine.diseasePulmonary embolismSurgeryAcute Disease; Aged; Aged 80 and over; Blood Pressure; Female; Heart Rate; Humans; Male; Middle Aged; Prognosis; Pulmonary Embolism; Reproducibility of Results; Retrospective Studies; Risk Assessment; Spain; Troponin I; Ventricular Function Right; Pulmonary and Respiratory Medicine; Critical Care and Intensive Care Medicine; Cardiology and Cardiovascular MedicineRightSpainAcute DiseaseCohortVentricular Function RightFemalePulmonary EmbolismCardiology and Cardiovascular MedicineRisk assessmentbusinessChest
researchProduct

Prognostic significance of cyclin D1 in esophageal squamous cell carcinoma patients treated with surgery alone or combined therapy modalities.

1999

In the present study, the expression of cyclin D1, as detected by immunohistochemistry, was compared with other prognostic variables and its prognostic impact was evaluated in a group of 172 patients with squamous cell carcinoma (SCC) of the esophagus who underwent potentially curative resection therapy and in a second group of 38 patients with SCC of the esophagus who were treated by combined modality therapy (radiochemotherapy ± surgery). Expression of cyclin D1 in surgically treated carcinomas correlated negatively with tumor differentiation (p = 0.026) but positively with mitotic activity (p = 0.0199) and nodal status (p = 0.040). There were no significant correlations with pT category.…

OncologyAdultMaleCancer Researchmedicine.medical_specialtyPrognostic variableEsophageal Neoplasmsmedicine.medical_treatmentLeucovorinCyclin D1EsophagusInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineBiomarkers TumorHumansCyclin D1EsophagusAgedEpirubicinAged 80 and overMucous MembraneEsophageal diseasebusiness.industryCancerEsophageal cancerMiddle Agedmedicine.diseasePrognosisCombined Modality TherapySurgeryRadiation therapySurvival Ratemedicine.anatomical_structureOncologyEpidermoid carcinomaCarcinoma Squamous CellFemaleFluorouracilCisplatinbusinessInternational journal of cancer
researchProduct

Impact of trastuzumab treatment beyond disease progression for advanced/metastatic breast cancer on survival - results from a prospective, observatio…

2013

Abstract Objectives Evidence suggests that continued trastuzumab therapy beyond progression (TBP) may provide additional survival benefit. Within the framework of an observational prospective study of patients with advanced/metastatic breast cancer receiving trastuzumab in routine clinical practice, we had the opportunity to examine the effect of TBP in a large population. Patients and methods Among a total of 1843 trastuzumab-treated patients, a sub-cohort of 418 fulfilled the selection criteria for the TBP analysis: 261 continued trastuzumab and 157 discontinued. Logrank tests and Cox models were used to compare survival and identify prognostic factors. Results Survival from progression w…

OncologyAdultPrognostic variablemedicine.medical_specialtyMultivariate analysisAntineoplastic AgentsBreast NeoplasmsAntibodies Monoclonal HumanizedBreast cancerTrastuzumabInternal medicineGermanymedicineHumansProspective StudiesNeoplasm MetastasisProspective cohort studyAgedAged 80 and overProportional hazards modelbusiness.industryGeneral MedicineMiddle AgedTrastuzumabmedicine.diseaseMetastatic breast cancerSurvival AnalysisSurgeryTreatment OutcomeConcomitantDisease ProgressionSurgeryFemalebusinessmedicine.drugFollow-Up StudiesBreast (Edinburgh, Scotland)
researchProduct

Old and new immunophenotypic markers in multiple myeloma for discrimination of responding and relapsing patients: The importance of “normal” residual…

2015

Background Multiple myeloma is an incurable disease characterized by proliferation of clonal malignant plasma cells (CPCs), which can be immunophenotypically distinguished from polyclonal plasma cells (PPCs) by multiparameter flow cytometry (MFC). The utility of PPCs analysis in detecting prognostic and predictive information is still a matter of debate. Methods: we tested the ability of 11 MFC markers in detecting differences in the immunophenotype of CPCs and PPCs among patients in various disease stages; we verified if these markers could be associated with disease stage/response to therapy despite the role of clinical parameters. Results: significant changes in the expression of markers…

OncologyCD20Prognostic variablemedicine.medical_specialtyPathologyHistologybiologybusiness.industryCD58Cell BiologyPlasma cellmedicine.diseasePathology and Forensic Medicinemedicine.anatomical_structureImmunophenotypingInternal medicinemedicinebiology.proteinStage (cooking)businessCytometryMultiple myelomaCytometry Part B: Clinical Cytometry
researchProduct

In the literature: October 2020.

2020

Immune checkpoint inhibitors are widely used as treatment for an increasing number of solid tumours. Nevertheless, the lack of predictive biomarker represents a limitation across several cancer types. During the last years, the possibility to dynamically study tumour evolution through circulating tumour DNA (ctDNA) in plasma has opened novel possibility in evaluating disease status and therapeutic response, especially in localised disease to predict the possibility of relapse. However, the specific opportunities for application in the context of immunotherapy remain to be clarified.1 In an article recently published in Cancer Discovery by Zhang et al ,2 a comprehensive analysis of ctDNA dat…

OncologyCancer Researchmedicine.medical_specialtyPrognostic variableDurvalumabbusiness.industryCancerMicrosatellite instabilityContext (language use)DiseaseNewsmedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenslcsh:RC254-282not applicableOncologyInternal medicinemedicine1506Lung cancerbusinessTremelimumabmedicine.drugESMO open
researchProduct

FcγRIIa and Fc γ RIIIa Polymorphisms and Cetuximab Benefit in the Microscopic Disease

2014

Abstract Purpose: FcγR polymorphisms have been reported to enhance the immune-mediated effects of cetuximab in metastatic colorectal cancer. There are no data on the relationship between these polymorphisms and cetuximab in the early-stage setting. We performed a pharmacogenomic analysis of EXPERT-C, a randomized phase II trial of neoadjuvant CAPOX followed by chemoradiotherapy, surgery, and adjuvant CAPOX ± cetuximab in high-risk, locally advanced rectal cancer. Experimental Design: FcγRIIa-H131R and FcγRIIIa-V158F polymorphisms were analyzed on DNA from peripheral blood samples. Kaplan–Meier method and Cox regression analysis were used to calculate survival estimates and compare treatment…

OncologyCancer Researchmedicine.medical_specialtyPrognostic variableGenotypeColorectal cancermedicine.medical_treatmentCetuximabAntibodies Monoclonal HumanizedDisease-Free SurvivalInternal medicineGenotypemedicineHumansGenotypingCetuximabProportional hazards modelbusiness.industryReceptors IgGPrognosismedicine.diseaseErbB ReceptorsTreatment OutcomeOncologyImmunologyColorectal NeoplasmsbusinessAdjuvantChemoradiotherapymedicine.drugClinical Cancer Research
researchProduct

Using Cox's proportional hazards model for prognostication in carcinoma of the upper aero-digestive tract.

1992

One of the major short comings of the traditional TNM system is its limited potential for prognostication. With the development of multifactorial analysis techniques, such as Cox's proportional hazards model, it has become possible to simultaneously evaluate a large number of prognostic variables. Cox's model allows both the identification of prognostically relevant variables and the quantification of their prognostic influence. These characteristics make it a helpful tool for analysis as well as for prognostication. The goal of the present study was to develop a prognostic index for patients with carcinoma of the upper aero-digestive tract which makes use of all prognostically relevant var…

OncologyLarynxAdultMalePrognostic variablePathologymedicine.medical_specialty03 medical and health sciencesMultifactorial analysis0302 clinical medicineSurvival dataInternal medicinemedicineCarcinomaHumansBasal cell030223 otorhinolaryngologyAgedNeoplasm StagingProportional Hazards ModelsAged 80 and overHypopharyngeal NeoplasmsProportional hazards modelbusiness.industryGeneral MedicineMiddle Agedmedicine.diseasePrognosisSurvival Ratestomatognathic diseasesOropharyngeal Neoplasmsmedicine.anatomical_structureOtorhinolaryngology030220 oncology & carcinogenesisCarcinoma Squamous CellDigestive tractFemaleMouth NeoplasmsbusinessActa oto-laryngologica
researchProduct